Fluorine-18 FAPI 74
Alternative Names: [18F]FAPI-74Latest Information Update: 10 Sep 2025
At a glance
- Originator University of Heidelberg
- Developer SOFIE
- Class Fluorine radioisotopes; Imaging agents; Quinolines; Radioisotopes; Radiopharmaceutical diagnostics
- Mechanism of Action Positron-emission tomography enhancers
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Phase II/III Fever of unknown origin
- Phase II Gastrointestinal cancer
- Phase I Solid tumours
Most Recent Events
- 27 Aug 2025 Phase-II/III clinical trials in Fever of unknown origin (Diagnosis) in Belgium (IV) (CTIS2024-516464-28-00)
- 19 Jun 2025 GE Healthcare in collaboration with Leiden University Medical Center plans a phase II/III PLASTIC-3 trial in Adenocarcinoma (Diagnosis) in Netherlands (IV) in June 2025 (NCT07018661)
- 15 Jan 2025 18-F FAPI 74 is available for licensing as of 15 Jan 2025. www.sofie.com